OC
IOVA icon

Oppenheimer & Co’s Iovance Biotherapeutics IOVA Stock Holding History

Oppenheimer & Co’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-15,342
Closed -$144K – 1603
2024
Q3 		$144K Sell
15,342
-566
-4% -$5.36K ﹤0.01% 1437
2024
Q2 		$128K Sell
15,908
-717
-4% -$7.68K ﹤0.01% 1375
2024
Q1 		$246K Buy
+16,625
New +$194K ﹤0.01% 1252
2022
Q2 		– Sell
-10,196
Closed -$170K – 1475
2022
Q1 		$170K Sell
10,196
-1,671
-14% -$25.8K ﹤0.01% 1378
2021
Q4 		$227K Sell
11,867
-3,587
-23% -$79K ﹤0.01% 1346
2021
Q3 		$381K Buy
15,454
+115
+0.7% +$2.71K 0.01% 1125
2021
Q2 		$399K Sell
15,339
-1,348
-8% -$35K 0.01% 1117
2021
Q1 		$528K Sell
16,687
-2,389
-13% -$99K 0.01% 943
2020
Q4 		$885K Sell
19,076
-4,690
-20% -$186K 0.02% 689
2020
Q3 		$783K Buy
23,766
+3,744
+19% +$115K 0.02% 668
2020
Q2 		$549K Buy
+20,022
New +$658K 0.01% 774

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return

Oppenheimer & Co's IOVA Position: Q4 2024 in Review

Oppenheimer & Co sold out of Iovance Biotherapeutics (IOVA) in Q4 2024, closing a stake of 15,342 shares — an estimated $144K sold.

Oppenheimer & Co first reported a position in IOVA in Q2 2020 and held it in 11 quarters. The position peaked at $885K in Q4 2020. 301 funds tracked by Wall St. Rank hold IOVA as of Q4 2024.

  • Oppenheimer & Co reported no remaining Iovance Biotherapeutics position as of Q4 2024 after selling out during the quarter.
  • Oppenheimer & Co sold 15,342 Iovance Biotherapeutics shares in Q4 2024, an estimated $144K.
  • Oppenheimer & Co first reported a position in Iovance Biotherapeutics in Q2 2020 and held it in 11 quarters.
  • Oppenheimer & Co's Iovance Biotherapeutics position peaked at $885K in Q4 2020.
  • 301 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2024.

Based on Oppenheimer & Co's 13F filing for Q4 2024, filed 5 Feb 2025.